Physician profile
Eric Cary Brooks
NPI 1689707333
$2,921.14
in general payments reported to CMS, 2019-2025
13 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $81.69 · 2021: $236 · 2022: $236 · 2023: $490 · 2024: $886 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,039.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $619.09 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $482.62 | 2023-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $448.02 | 2023-2024 | Rexulti, Nuedexta |
| Avanir Pharmaceuticals, INC. | $243.66 | 2019-2022 | |
| Abbott Laboratories | $228.00 | 2024 | Proclaim |
| Astrazeneca Pharmaceuticals LP | $186.37 | 2020-2021 | |
| W. L. Gore & Associates, INC. | $172.86 | 2019 | |
| Evoke Pharma, INC. | $124.99 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 2025 | Cobenfy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.16 | 2021 | |
| Sumitomo Pharma America, INC. | $82.70 | 2023-2024 | Aptiom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.39 | 2019 | |
| Sun Pharmaceutical Industries INC. | $43.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.